Cardiac Biomarker Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global cardiac biomarker market looks promising with opportunities in myocardial infarction, congestive heart failure, acute coronary syndrome, and atherosclerosis. The global cardiac biomarker market is expected to grow with a CAGR of 18%-20% from 2020 to 2025. The major drivers for this market are increasing prevalence of cardiovascular diseases, rising development of biomarkers, and increasing preference for point-of-care cardiac testing kits.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global cardiac biomarker market report, please download the report brochure.
In this market, troponins is the largest type of cardiac biomarker, whereas point-of-care is the largest location of testing. Growth in various segments of the cardiac biomarker market are given below:
The study includes trends and forecast for the global cardiac biomarker market by type, location of testing, application, and region as follows:
By Type [Value ($ Million) shipment analysis for 2014 – 2025]:
Lucintel forecasts that troponins will remain the largest type segment over the forecast period due to its ability to detect the cardiac events of acute coronary syndrome (ACS) more accurately than other tests.
Within this market, point-of-care (POC) will remain the largest segment by location of testing over the forecast period due to its feature of easy to handle, user friendly, high accuracy, quick outcomes, and economic pricing.
North America will remain the largest region over the forecast period due to rising awareness of cardiac diagnostics solutions, increasing geriatric population, and increasing incidence of coronary heart diseases in the region.
Features of the Global Cardiac Biomarker Market
Q.1 What are some of the most promising potential, high-growth opportunities for the global cardiac biomarker market by type (myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, and ischemia modified albumin (IMA)), location of testing (point of care and laboratories), application (myocardial infarction, congestive heart failure, acute coronary syndrome, and atherosclerosis), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global cardiac biomarker market?
Q.5 What are the business risks and threats to the global cardiac biomarker market?
Q.6 What are the emerging trends in this cardiac biomarker market and the reasons behind them?
Q.7 What are some changing demands of customers in this cardiac biomarker market?
Q.8 What are the new developments in the cardiac biomarker market? Which companies are leading these developments?
Q.9 Who are the major players in the cardiac biomarker market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in the cardiac biomarker market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global cardiac biomarker market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecast, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Ventures, and Company Profiling
Market Segments Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, and Ischemia Modified Albumin (IMA)), Location of Testing (Point of Care and Laboratories), and Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Atherosclerosis)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the global cardiac biomarker market looks promising with opportunities in myocardial infarction, congestive heart failure, acute coronary syndrome, and atherosclerosis. The global cardiac biomarker market is expected to grow with a CAGR of 18%-20% from 2020 to 2025. The major drivers for this market are increasing prevalence of cardiovascular diseases, rising development of biomarkers, and increasing preference for point-of-care cardiac testing kits.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global cardiac biomarker market report, please download the report brochure.
In this market, troponins is the largest type of cardiac biomarker, whereas point-of-care is the largest location of testing. Growth in various segments of the cardiac biomarker market are given below:
The study includes trends and forecast for the global cardiac biomarker market by type, location of testing, application, and region as follows:
By Type [Value ($ Million) shipment analysis for 2014 – 2025]:
- Myocardial Muscle Creatine Kinase (CK-MB)
- Troponins (T and I)
- Myoglobin
- Brain Natriuretic Peptide (BNPs) or NT-proBNP
- Ischemia Modified Albumin (IMA)
- Point of Care
- Laboratories
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- The Rest of the World
- Brazil
Lucintel forecasts that troponins will remain the largest type segment over the forecast period due to its ability to detect the cardiac events of acute coronary syndrome (ACS) more accurately than other tests.
Within this market, point-of-care (POC) will remain the largest segment by location of testing over the forecast period due to its feature of easy to handle, user friendly, high accuracy, quick outcomes, and economic pricing.
North America will remain the largest region over the forecast period due to rising awareness of cardiac diagnostics solutions, increasing geriatric population, and increasing incidence of coronary heart diseases in the region.
Features of the Global Cardiac Biomarker Market
- Market Size Estimates: Global cardiac biomarker market size estimation in terms of value ($M) shipment.
- Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.
- Segmentation Analysis: Global cardiac biomarker market size by various segments, such as type, location of testing, and application, in terms of value.
- Regional Analysis: Global cardiac biomarker market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different types, locations of testing, applications, and regions for the global cardiac biomarker market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global cardiac biomarker market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
Q.1 What are some of the most promising potential, high-growth opportunities for the global cardiac biomarker market by type (myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, and ischemia modified albumin (IMA)), location of testing (point of care and laboratories), application (myocardial infarction, congestive heart failure, acute coronary syndrome, and atherosclerosis), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global cardiac biomarker market?
Q.5 What are the business risks and threats to the global cardiac biomarker market?
Q.6 What are the emerging trends in this cardiac biomarker market and the reasons behind them?
Q.7 What are some changing demands of customers in this cardiac biomarker market?
Q.8 What are the new developments in the cardiac biomarker market? Which companies are leading these developments?
Q.9 Who are the major players in the cardiac biomarker market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in the cardiac biomarker market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global cardiac biomarker market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecast, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Ventures, and Company Profiling
Market Segments Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, and Ischemia Modified Albumin (IMA)), Location of Testing (Point of Care and Laboratories), and Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Atherosclerosis)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Cardiac Biomarker Market Trends and Forecast
3.3: Global Cardiac Biomarker Market by Type
3.3.1: Myocardial Muscle Creatine Kinase (CK-MB)
3.3.2: Troponins (T and I)
3.3.3: Myoglobin
3.3.4: Brain Natriuretic Peptide (BNPs) or NT-proBNP)
3.3.5: Ischemia Modified Albumin (IMA)
3.4: Global Cardiac Biomarker Market by Location of Testing
3.4.1: Point of Care
3.4.2: Laboratories
3.5: Global Cardiac Biomarker Market by Application
3.5.1: Myocardial Infarction
3.5.2: Congestive Heart Failure
3.5.3: Acute Coronary Syndrome
3.5.4: Atherosclerosis
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Cardiac Biomarker Market by Region
4.2: North American Cardiac Biomarker Market
4.2.1: Market by Type: Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)
4.2.2: Market by Location of Testing: Point of Care and Laboratories
4.2.3: Market by Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis
4.2.4: The United States Cardiac Biomarker Market
4.2.5: The Canadian Cardiac Biomarker Market
4.2.6: The Mexican Cardiac Biomarker Market
4.3: European Cardiac Biomarker Market
4.3.1: Market by Type: Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)
4.3.2: Market by Location of Testing: Point of Care and Laboratories
4.3.3: Market by Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis
4.3.4: The Cardiac Biomarker Market of the United Kingdom
4.3.5: The German Cardiac Biomarker Market
4.3.6: The French Cardiac Biomarker Market
4.4: APAC Cardiac Biomarker Market
4.4.1: Market by Type: Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)
4.4.2: Market by Location of Testing: Point of Care and Laboratories
4.4.3: Market by Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis
4.4.4: The Chinese Cardiac Biomarker Market
4.4.5: The Indian Cardiac Biomarker Market
4.4.6: The Japanese Cardiac Biomarker Market
4.5: ROW Cardiac Biomarker Market
4.5.1: Market by Type: Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)
4.5.2: Market by Location of Testing: Point of Care and Laboratories
4.5.3: Market by Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis
4.5.4: Brazilian Cardiac Biomarker Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Cardiac Biomarker Market by Type
7.1.2: Growth Opportunities for the Global Cardiac Biomarker Market by Location of Testing
7.1.3: Growth Opportunities for the Global Cardiac Biomarker Market by Application
7.1.4: Growth Opportunities for the Global Cardiac Biomarker Market by Region
7.2: Emerging Trends in the Global Cardiac Biomarker Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Cardiac Biomarker Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cardiac Biomarker Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Roche Diagnostics
8.2: Abbott Laboratories
8.3: Siemens Healthcare
8.4: Alere Inc.
8.5: Becton, Dickinson and Company
8.6: Bio-Rad Laboratories
8.7: BioMerieux
8.8: Randox laboratories
8.9: Beckman Coulter
8.10: Therm Fisher Scientific
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Cardiac Biomarker Market Trends and Forecast
3.3: Global Cardiac Biomarker Market by Type
3.3.1: Myocardial Muscle Creatine Kinase (CK-MB)
3.3.2: Troponins (T and I)
3.3.3: Myoglobin
3.3.4: Brain Natriuretic Peptide (BNPs) or NT-proBNP)
3.3.5: Ischemia Modified Albumin (IMA)
3.4: Global Cardiac Biomarker Market by Location of Testing
3.4.1: Point of Care
3.4.2: Laboratories
3.5: Global Cardiac Biomarker Market by Application
3.5.1: Myocardial Infarction
3.5.2: Congestive Heart Failure
3.5.3: Acute Coronary Syndrome
3.5.4: Atherosclerosis
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Cardiac Biomarker Market by Region
4.2: North American Cardiac Biomarker Market
4.2.1: Market by Type: Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)
4.2.2: Market by Location of Testing: Point of Care and Laboratories
4.2.3: Market by Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis
4.2.4: The United States Cardiac Biomarker Market
4.2.5: The Canadian Cardiac Biomarker Market
4.2.6: The Mexican Cardiac Biomarker Market
4.3: European Cardiac Biomarker Market
4.3.1: Market by Type: Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)
4.3.2: Market by Location of Testing: Point of Care and Laboratories
4.3.3: Market by Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis
4.3.4: The Cardiac Biomarker Market of the United Kingdom
4.3.5: The German Cardiac Biomarker Market
4.3.6: The French Cardiac Biomarker Market
4.4: APAC Cardiac Biomarker Market
4.4.1: Market by Type: Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)
4.4.2: Market by Location of Testing: Point of Care and Laboratories
4.4.3: Market by Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis
4.4.4: The Chinese Cardiac Biomarker Market
4.4.5: The Indian Cardiac Biomarker Market
4.4.6: The Japanese Cardiac Biomarker Market
4.5: ROW Cardiac Biomarker Market
4.5.1: Market by Type: Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)
4.5.2: Market by Location of Testing: Point of Care and Laboratories
4.5.3: Market by Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis
4.5.4: Brazilian Cardiac Biomarker Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Cardiac Biomarker Market by Type
7.1.2: Growth Opportunities for the Global Cardiac Biomarker Market by Location of Testing
7.1.3: Growth Opportunities for the Global Cardiac Biomarker Market by Application
7.1.4: Growth Opportunities for the Global Cardiac Biomarker Market by Region
7.2: Emerging Trends in the Global Cardiac Biomarker Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Cardiac Biomarker Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cardiac Biomarker Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Roche Diagnostics
8.2: Abbott Laboratories
8.3: Siemens Healthcare
8.4: Alere Inc.
8.5: Becton, Dickinson and Company
8.6: Bio-Rad Laboratories
8.7: BioMerieux
8.8: Randox laboratories
8.9: Beckman Coulter
8.10: Therm Fisher Scientific
